Good morning, and welcome to the Avacta Group Plc investor presentation. [Operator Instructions] Before we begin, we'd like to submit the following poll. I'd now like to hand you over to Christina ...

Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer Data from first ...

Good day, everyone. My name is Megan, and I will be your conference operator today. At this time, I would like to welcome you to Xencor XmAb819 Initial Phase I Dose Escalation Results Webcast.

PepGen has shared positive initial data from its ongoing FREEDOM-DM1 Phase I trial, which is evaluating PGN-EDODM1 in patients with myotonic dystrophy type 1 (DM1). In the 5mg/kg and 10mg/kg dose ...

Abdera Therapeutics has reported initial data from its Phase Ia study of the radiopharmaceutical biologic therapy, ABD-147, in treating individuals with small cell lung cancer (SCLC) and large cell ...

Based on positive safety and efficacy data in the Phase 1/2 dose escalation phase of the all-in-one study, Genethon expects to launch pivotal trial in Europe in 2025 and in the US. The results showed ...

Tenaya Therapeutics, Inc., a biotechnology company focused on developing therapies for heart disease, will announce initial data from the MyPEAK-1 Phase 1b/2 clinical trial of its gene therapy TN-201 ...